Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Key Factors Distinguish Transient Post-Stroke Symptoms

Published: Tue, 15 Aug 2017 14:38:27 EDT
Investigators have identified key risk factors, triggers, and clinical features of transient post-stroke recrudescence in findings that may help clinicians distinguish this phenomenon from new stroke symptoms.
Medscape Medical News

New Anti-VEGF Drug Promising for Wet Macular Degeneration

Published: Tue, 15 Aug 2017 14:16:11 EDT
OPT-302, a new vascular endothelial growth factor (VEGF) inhibitor, appears to be safe and shows signs it could slow the progression of neovascular age-related macular degeneration.
Medscape Medical News

Noninvasive Method May Tell Alzheimer's From FTD

Published: Tue, 15 Aug 2017 13:37:42 EDT
A new method using transcranial magnetic stimulation may help differentiate Alzheimer's disease from frontotemporal dementia, new research shows.
Medscape Medical News

NAMS' Hormone Therapy Statement: Primary Care Takeaways

Published: Tue, 15 Aug 2017 12:43:14 EDT
Who can safely take hormone therapy and for how long? Are there alternatives? Dr JoAnn Manson answers questions based on the new position statement from the North American Menopause Society.
Medscape Internal Medicine
Displaying results 17-20 (of 20)
 1 - 2 - 3 - 4 - 5 


Chutes & Ladders—David Epstein expands title at Rubius to executive chairman

Published: Thu, 10 Aug 2017 20:53:59 +0000
David Epstein was named executive chairman of Rubius Therapeutics, ex-PTC executive Mark Rothera jumped ship to helm Orchard Therapeutics and Maverick tapped former Pacira COO James Scibetta as CEO. Plus more hirings, firings and retirings throughout the industry.

RNA-targeting CRISPR could yield treatments for Huntington's, ALS

Published: Thu, 10 Aug 2017 15:58:20 +0000
Researchers from the University of California, San Diego, have used a new version of CRISPR to fix problems in RNA rather than to edit DNA, a promising step for a group of diseases, including Huntington’s and amyotrophic lateral sclerosis, that have no cure.

Galapagos to take IPF drug into late-stage trial after phase 2 win

Published: Thu, 10 Aug 2017 11:44:20 +0000
Belgian biotech Galapagos has chalked up a positive phase 2a trial for its idiopathic pulmonary fibrosis (IPF) drug GLPG1690, saying it halted the relentless decline in lung function normally seen in patients.

Orchard Therapeutics hires ex-PTC executive Mark Rothera as new CEO

Published: Thu, 10 Aug 2017 09:22:48 +0000
Fierce 15 winner and ultrarare disease startup Orchard Therapeutics has taken on Mark Rothera as its new president and chief. Rothera comes to Orchard from controversial biotech PTC Therapeutics, where he served as its chief commercial officer.
Displaying results 17-20 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy